Nama's AI scorecard currently rates Globus Medical Strong Buy (8.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is GMED's P/E ratio?

Globus Medical trades at a trailing price-to-earnings ratio of 14.3.

When does GMED report earnings?

Globus Medical's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $1.34.

What is the GMED price target?

The median analyst price target from 13 analysts is $100.00, with a range of $84.00 – $125.00.

Is GMED Shariah compliant?

Nama's AAOIFI-style screen reads Globus Medical as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Globus Medical (GMED)

Healthcare · Medical Devices · NYSE

Globus Medical (GMED) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $9.54B, a trailing price-to-earnings ratio of 14.3 and a free-cash-flow yield of 5.9%. Over the most recent reported fiscal year, revenue grew 16.6% and free cash flow per share grew 43.7%. Nama's AI scorecard rates it Strong Buy, 8.9 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Strong Buy · 8.9/10

The top band of the Fundamental Verdict (8.6–10). As of Nov 7, 2026.

Momentum

Middle · +19.5% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-29.9%

How far the last close sits under the highest price of the past five years.

Market cap	$9.54B
Trailing P/E	14.3
Price / book	2.0
Price / sales	3.0
FCF yield	5.9%
Dividend yield	—
Gross margin	68.5%
Operating margin	21.4%
Net margin	17.0%
Revenue growth (YoY)	+16.6%
Revenue growth (3-yr annual)	+42.2%
EPS growth (YoY)	+27.4%
FCF/share growth (YoY)	+43.7%
Beta	1.0
Exchange	NYSE
Sector	Healthcare
Industry	Medical Devices

GMED earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate $1.34). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$1.23	$1.20	+2.5%	—
Q2 2026	Aug 6, 2026	$1.34	$1.10	+21.8%	$789.61M
Q1 2026	May 7, 2026	$1.12	$0.92	+21.7%	$759.85M
Q4 2025	Feb 24, 2026	$1.28	$1.15	+11.3%	$826.42M

GMED analyst price target

Median target $100.00 from 13 analysts, ranging $84.00 – $125.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7

Explore live GMED data on Nama Insights →

Recent Congressional trades

Globus Medical trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Oct 12, 2026
Gilbert Cisneros	House	Buy	$15,001 - $50,000	Sep 10, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Apr 7, 2026
Lisa McClain	House	Sell	$1,001 - $15,000	Aug 13, 2025
Lisa McClain	House	Sell	$1,001 - $15,000	Aug 13, 2025
Lisa McClain	House	Buy	$1,001 - $15,000	Aug 13, 2025
Josh Gottheimer	House	Sell	$1,001 - $15,000	May 14, 2025
Thomas R Tillis	Senate	Sell	$1,001 - $15,000	—

GMED FAQ

Is GMED a buy?: Nama's AI scorecard currently rates Globus Medical Strong Buy (8.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is GMED's P/E ratio?: Globus Medical trades at a trailing price-to-earnings ratio of 14.3.
When does GMED report earnings?: Globus Medical's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $1.34.
What is the GMED price target?: The median analyst price target from 13 analysts is $100.00, with a range of $84.00 – $125.00.
Is GMED Shariah compliant?: Nama's AAOIFI-style screen reads Globus Medical as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.